<DOC>
	<DOCNO>NCT02736149</DOCNO>
	<brief_summary>Ubenimex develop treatment pulmonary arterial hypertension ( PAH ) ( World Health Organization [ WHO ] Group 1 ) improve exercise capacity delay clinical worsening . This study Phase 2 , open-label , multicenter , extension study evaluate long-term safety efficacy ubenimex patient PAH ( WHO Group 1 ) complete Study EIG-UBX-001 ( Study EIG-UBX-001 Phase 2 , randomize , double-blind , placebo-controlled clinical trial ) meet eligibility criterion Study EIG-UBX-002 . The primary objective study : - obtain long-term safety tolerability data ubenimex ( 150 mg administer three time daily [ TID ] ) patient PAH ( WHO Group 1 ) .</brief_summary>
	<brief_title>Open-Label Extension Study Ubenimex Patients With Pulmonary Arterial Hypertension ( WHO Group 1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Ubenimex</mesh_term>
	<criteria>Patients must complete Study EIGUBX001 Week 24 . In opinion Principal Investigator , generally compliant study requirement Study EIGUBX001 . Agrees use medically acceptable method contraception throughout entire study period . Willing able comply schedule visit , treatment plan , laboratory test study procedure . Is pregnant lactate . Concurrent regular use another leukotriene pathway inhibitor . Any reason , opinion investigator , precludes patient participate study . 1 . Any condition unstable could jeopardize safety patient his/her compliance study 2 . A serious uncontrolled medical disorder/condition opinion investigator would impair ability patient receive protocol therapy An ongoing , drugrelated , serious adverse event ( SAE ) . Significant/chronic renal insufficiency . Transaminases ( alanine transaminase , aspartate transaminase ) level &gt; 3 × upper limit normal ( ULN ) and/or bilirubin level &gt; 2 × ULN . Absolute neutrophil count &lt; 1500 mm3 . Hemoglobin concentration &lt; 9 g/dL Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>